Alder BioPharmaceuticals, Inc. Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 13, 2017 17:52 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., July 13, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate...
Alder BioPharmaceuticals, Inc. Prices Public Offering of Common Stock
July 12, 2017 18:53 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., July 12, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate...
Alder BioPharmaceuticals, Inc. Announces Commencement of Public Offering of Common Stock
July 11, 2017 16:27 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., July 11, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate...
Alder BioPharmaceuticals Announces Positive Eptinezumab Phase 3 Results for Prevention of Frequent Episodic Migraine
June 27, 2017 07:00 ET
|
Alder BioPharmaceuticals, Inc.
-- Pivotal PROMISE 1 top-line results show eptinezumab met primary and key secondary endpoints -- -- Beginning day 1 after first dose significant reduction in proportion of patients experiencing...
Alder to Present Migraine Prevention Data for Eptinezumab at 59th Annual Scientific Meeting of the American Headache Society
June 07, 2017 12:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., June 07, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), today announced four data presentations at the 59th Annual Scientific Meeting of the American Headache...
Alder BioPharmaceuticals® to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
May 10, 2017 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., May 10, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced...
Alder BioPharmaceuticals Presents Positive Phase 2b Study Data for Eptinezumab at 69th Annual American Academy of Neurology Meeting
April 28, 2017 13:24 ET
|
Alder BioPharmaceuticals, Inc.
- Eptinezumab emerging clinical profile suggests migraine preventative benefit achieved as soon as 24 to 48 hours after a single infusion - BOTHELL, Wash., April 28, 2017 (GLOBE NEWSWIRE) --...
Alder BioPharmaceuticals® Announces First Quarter 2017 Financial and Operating Results
April 27, 2017 16:05 ET
|
Alder BioPharmaceuticals, Inc.
Top-line data from pivotal PROMISE 1 study of eptinezumab for migraine prevention on track to be announced 2Q 2017Conference call set for 5 p.m. EDT todayBOTHELL, Wash., April 27, 2017 (GLOBE...
Alder BioPharmaceuticals Presents Additional Data from Eptinezumab Development Program at 69th Annual American Academy of Neurology Meeting
April 24, 2017 08:30 ET
|
Alder BioPharmaceuticals, Inc.
- Eptinezumab rational design results in differentiated clinical profile for migraine prevention therapy - - Eptinezumab responders showed significant and sustained reduction in migraine days...
Alder BioPharmaceuticals to Host Conference Call to Discuss First Quarter 2017 Financial and Operating Results
April 20, 2017 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 20, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals®, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today...